State of the Art Sexual Health Pathogen Detection

The Absolute Genomics Sexual Health InSITE Panel is an RT-PCR-based assay with a proven track record of high specificity and sensitivity. Traditional methods involving culturing and microscopy are time consuming and have lower accuracy / sensitivity. The panel is a faster and more reliable solution for detecting HIV, Syphilis, Hepatitis B, Hepatitis C, Chlamydia, and Gonorrhea. The Panel has 8 targets which were selected based on epidemiological data and feedback from our client pool. The results have turnaround times under 24 hours thereby allowing a quick identification of disease and early treatment. All bacterial targets if detected are subsequently tested for antibiotic resistance markers and the information provided in Arkstone Antimicrobial Resistance Report that provides the best treatment option for detected pathogens.

Clinical Need :

1 in 5 people in the US have an STI
There were 68 million STI infections in USA in 2018
70% of Gonorrhea, 63% of Chlamydia, 26% of HIV and 20% of Syphilis cases are in youth aged 15-24.
New STIs total nearly $16 billion in direct medical costs
Gonorrhea is expected to eventually wear down our last highly effective antibiotic due to antibiotic resistance
Patients with co-infections depend on accurate and timely diagnosis to be treated in time
Major advantages of the PCR technique are higher accuracy, quicker turnaround time, and a comprehensive report

STD rates in the U.S. hit a new high for the 6th straight year

~2.5 million Americans suffer from STD infections annually

Nearly 30% increase in reportable STDs between 2015 - 2019

ABx Advantage

The Absolute Genomics ABx Advantage gene panel is designed to detect significant classes of antibiotic resistance. In addition, this panel can identify the presence of specific resistance genes that are involved in drug inhibition. The Absolute Genomics ABx Advantage gene panel has 11 antibiotic resistance genes belonging to aminoglycosides, β-lactamase, fluoroquinolone, macrolide, tetracycline, vancomycin, and multi-drug resistance classifications. The data is used for providing antibiotic resistance stewardship via Arkstone Medical Solutions. The one-choice report powered by Arkstone Medical Solutions for the ABx Advantage gene panel converts PCR data into simple interpretations for physicians to help them make better treatment decisions. This technology is a combination of software artificial intelligence and human expertise.

The antimicrobial report contains a unique ArkScore to help prescribers make informed decisions.
The antimicrobial decision engine combines machine-learning artificial intelligence with decades of deep infectious disease expertise to guide physicians to a singular treatment regimen that targets the most relevant infection with the lowest risk to the patient.
ArkScore describes the level of antimicrobial resistance expressed in organisms.
ArkScore provides the most effective treatment with the least risk of adverse events resulting in the reduction of unnecessary use of broad-spectrum antibiotics